[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burden\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burden":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617805","real-world-study-on-the-impact-of-atopic-dermatitis-from-a-caregiver-perspective-100617805",false,"NCT07323394","Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;\n2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);\n3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;\n4. Other parent or caregiver within the household of the child with atopic dermatitis.",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.",[24,25,26,27,28],"Atopic Dermatitis","Eczema Atopic Dermatitis","Eczema","Caregiver","Burden",[30,31,32],"atopic dermatitis","quality of life","real-world","NOT_YET_RECRUITING","2026-01-22",{"date":36,"type":37},"2026-01-23","ACTUAL",{"date":39,"type":20},"2026-01",{"date":41,"type":20},"2026-07",{"name":43,"class":44},"PeriPharm","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100593679","the-treatment-burden-of-myopic-choroidal-neovascularization-100593679","NCT07009574","The Treatment Burden of Myopic Choroidal Neovascularization","Factors Associated to Treatment Burden in Patients Affected by Myopic Choroidal Neovascularization","mCNV burden","Inclusion Criteria:\n\n* axial length\\>26 mm or refractive error (spherical equivalent) \\\u003C-6 Diopters\n* clinical changes typical of Pathologic myopia\n* diagnosis of subfoveal or juxtafoveal treatment-naïve myopic choroidal neovascularization (mCNV)\n* only one eye per patient was included in the analysis, in cases of patients treated bilaterally only the first eye treated was included\n\nExclusion Criteria:\n\n* Extrafoveal mCNV location\n* Other retinal diseases\n* any inflammatory condition which may cause CNV including multifocal choroiditis, puntate inner choroidopathy and white dot syndrome\n* previous ocular surgery (except for cataract extraction performed before the baseline visit)\n* inferior quality imaging",{"count":19,"type":20},"Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue. Myopic choroidal neovascularization (mCNV) is a well-known complication of PM, occurring in 5-11% of cases and representing a main cause of visual impairment in working people under the age of 50.\n\nThe management of patients affected by active mCNV have been revolutionized by the advent of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs.\n\nPatients affected by mCNV needs intravitreal injections and visits to assess the need of retreatment with assiduity. It represents a significant burden for patients, caregivers as well as medical equipe.\n\nThe aim of this study is to investigate the factors associated with the number of anti-VEGF injections and hospital visits necessary to get mCNV disease stabilization and to identify predictive factors of treatment burden.",[56,57,28],"Myopic Choroidal Neovascularisation","Anti-VEGF Treatment",[59,60,61,62,63],"mcnv","anti-vegf","myopic maculopathy","choroidal neovascularization","myopia","2025-06-03",{"date":66,"type":37},"2025-06-06",{"date":68,"type":20},"2025-06-01",{"date":70,"type":20},"2025-12-15",{"name":72,"class":44},"Policlinico Gaspare Rodolico - San Marco Catania",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":101},"100523843","patient-reported-outcome-and-patient-reported-experience-after-status-epilepticus-100523843","NCT06100978","Patient-reported Outcome and Patient-reported Experience After Status Epilepticus","Patient-reported Outcomes in Status Epilepticus Requiring Intensive Care Unit Management. A Multicenter Longitudinal Cohort Study","POSEIDON2","Inclusion Criteria:\n\n* Adults 18 years old or older\n* Patients previously included in the ICTAL registry (Status Epilepticus cohort NCT03457831)\n* Survivors after ICU management for Status Epilepticus More than 3 months and less than 5 years after ICU discharge\n\nExclusion Criteria:\n\n* Legal guardianship\n* Opposition to participate\n* Unread and unwritten French language\n* Patient not affiliated to a Social Security system",{"count":83,"type":20},145,"Status epilepticus (SE) is a common life-threatening neurological emergency in which prolonged or multiple closely spaced seizures can result in long-term impairments. SE remains associated with considerable mortality and morbidity, with little progress over the last three decades. The proportion of patients who die in the hospital is about 20% overall and 40% in patients with refractory SE. Morbidity is more difficult to evaluate, as adverse effects of SE are often difficult to differentiate from those attributed to the cause of SE. Our experience suggests that nearly 50% of patients may experience long-term functional impairments. The precise description of the consequences of these functional impairments and their impact on quality of life after SE requiring intensive care management has been little studied. Indeed, if cognitive, physical and mental impairments are now identified in the populations of patients who required intensive care under the term postresuscitation syndrome (PICS), neuronal lesions consecutive to the SE itselfor to its cause could be responsible for these different functional alterations.\n\nThus, the following have been described: (i) cognitive disorders in the areas of attention, executive functions and verbal fluency, visual and working memory disorders, but also spatio-temporal disorders; (ii) physical disorders such as the so-called post-resuscitation polyneuromyopathy; and (iii) mental disorders such as anxiety disorders, depressive states or those related to post-traumatic stress.\n\nAssessment and characterization of patient-reported outcomes is essential to complement the holistic assessment of clinically relevant outcomes from the patient's perspective. The POSEIDON study was a cross-sectional collection of PROs and HR-QOL components, and associated with patient functional outcomes, in those who required ICU management for status epilepticus. We propose here to continue the description of potential alterations after a subsequent ME, namely a longitudinal study (POSEIDON 2) which will also include the evaluation of patient-reported experience (PREMS) and the measurement of family burden.",[86,87,88,89,90,28,91],"Patient Reported Outcomes","Patient Satisfaction","Long Term Outcomes","Status Epilepticus","Intensive Care Unit","Relatives","RECRUITING","2024-11-04",{"date":95,"type":37},"2024-11-05",{"date":97,"type":37},"2024-05-25",{"date":41,"type":20},{"name":100,"class":44},"Versailles Hospital",13]